BioSpace News Archive

Data Supports Continued Dose Escalation and Further Investigation in Metastatic Renal Cell Carcinoma (mRCC)

Shipments for Follow-on Order Under Existing Supply Agreement Will Commence This Quarter

The Workers’ Compensation Benchmarking Study’s annual survey is underway.

Comp Resource Group has been recognized and awarded the 2019 Best of Delray Beach Award as the top Recruiting Agency by the Delray Beach Awards Program.

Nordic Nanovector ASA announces that following a safety review of the first patients in the ongoing Archer-1 trial investigating Betalutin® in combination with rituximab in second-line follicular lymphoma, the Betalutin® dose has been escalated to 15 MBq/kg for the next cohort of patients.

Kurin, Inc., the inventor and manufacturer of 510-cleared Kurin® blood culture collection sets, has received its CE Mark that allows product distribution into the European Economic Area and European Union Candidate Member States.

Investment will fund the commercial introduction of Cala Trio and expansion of the therapeutic platform

The National Council of Self-Insurers asked Joe Paduda to discuss how medical providers price their services to different payer groups at its 2019 Annual Meeting, June 9-12.

iX Biopharma Ltd announced that following the completion of its Phase 2 clinical study on Wafermine, a sublingual racemic ketamine wafer for the treatment of acute moderate to severe pain, the U.S. Food and Drug Administration has scheduled the End-of-Phase 2 meeting with the Company in the third quarter of 2019.

With a Performance by Multi-Platinum Pop Artist Andy Grammer and a Prelude Performance by The Ransom Notes at the Annual AcceptAbility Gala in DC